Workflow
定增
icon
Search documents
王力安防终止3亿元定增 2021年上市募资6.9亿元
Zhong Guo Jing Ji Wang· 2026-02-27 06:04
中国经济网北京2月27日讯 王力安防(605268.SH)昨晚披露了关于终止2024年度以简易程序向特定对 象发行股票事项的公告。 王力安防于2026年2月26日召开第四届董事会第二次会议,审议通过了《关于终止2024年度以简易 程序向特定对象发行股票事项的议案》。根据公司股东会的授权,该议案无需提交股东会审议。 王力安防表示,自公司首次公告以简易程序向特定对象发行股票事项以来,公司董事会、管理层与 中介机构等一直积极推进各项工作,经与保荐机构及相关中介深入沟通,综合考虑多方面因素,公司审 慎决定终止本次2024年度以简易程序向特定对象发行股票的相关事项。 王力安防2025年9月23日披露的2024年度以简易程序向特定对象发行A股股票预案(修订稿) 显示, 根据本次发行的竞价结果,发行对象拟认购金额合计为30,000万元,募集资金在扣除相关发行费用后的 募集资金净额将全部用于以下项目:湖北王力安防产品有限公司智能门窗系列产品项目。 截至预案公告日,公司控股股东为王力集团,持有上市公司19,372.50万股,持股比例43.41%;公 司实际控制人为王跃斌、陈晓君和王琛,三人直接及间接合计控制上市公司34,686 ...
光迅科技不超35亿元定增获深交所通过 申万宏源建功
Zhong Guo Jing Ji Wang· 2026-02-27 03:55
中国经济网北京2月27日讯光迅科技(002281)(002281.SZ)昨晚披露关于向特定对象发行股票申请获得 深圳证券交易所审核中心审核通过的公告称,公司于2026年2月26日收到深圳证券交易所出具的《关于 武汉光迅科技股份有限公司申请向特定对象发行股票的审核中心意见告知函》。深交所发行上市审核机 构对公司向特定对象发行股票的申请文件进行了审核,认为公司符合发行条件、上市条件和信息披露要 求,后续深交所将按规定报中国证券监督管理委员会履行相关注册程序。 中国信科集团为公司实际控制人,其同意以现金方式认购本次向特定对象发行股票,认购比例不低于本 次向特定对象发行股份总数的10%,且不超过本次向特定对象发行股份总数的30%。根据相关规定,中 国信科集团认购本次向特定对象发行股票构成关联交易。 公司本次向特定对象发行股票事项尚需获得中国证监会同意注册后方可实施,最终能否获得中国证监会 作出同意注册的决定及其时间尚存在不确定性,公司将根据该事项的进展情况按照相关规定及时履行信 息披露义务。 光迅科技2025年度向特定对象发行股票募集说明书(申报稿)显示,本次向特定对象发行股票的发行对象 为包括公司实际控制人中国信科 ...
科大讯飞不超40亿元定增获深交所通过 国元证券建功
Zhong Guo Jing Ji Wang· 2026-02-13 09:21
Core Viewpoint - The company, iFlytek, has received approval from the Shenzhen Stock Exchange for its application to issue shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Issuance Details - The total amount to be raised from the issuance is capped at 400 million yuan, which will be used for the Spark Education model, computing platform, and to supplement working capital [1][3]. - The issuance will involve no more than 100 million shares, representing 4.33% of the total share capital prior to the issuance [2][3]. - The pricing mechanism for the shares will be based on 80% of the average trading price over the 20 trading days preceding the issuance date [2]. Group 2: Specific Investors - The issuance will target no more than 35 specific investors, including Anhui Yanzhi Technology Co., Ltd., which is controlled by iFlytek's actual controller, Liu Qingfeng, and plans to subscribe for between 250 million yuan and 350 million yuan [2][3]. - The issuance constitutes a related party transaction due to the involvement of Yanzhi Technology, which is an affiliate of Liu Qingfeng [2]. Group 3: Control and Governance - Following the issuance, Liu Qingfeng's voting rights in iFlytek are expected to decrease slightly to between 11.16% and 11.26%, but he will remain the actual controller of the company [3]. - The lead underwriter for this issuance is Guoyuan Securities Co., Ltd., with representatives Zhu Peifeng and Liu Ziqi overseeing the process [3].
新希望不超33.38亿定增获深交所通过 招商证券建功
Zhong Guo Jing Ji Wang· 2026-02-13 07:42
中国经济网北京2月13日讯 新希望(000876.SZ)昨晚披露关于向特定对象发行股票申请获得深圳证券 交易所上市审核中心审核通过的公告称,公司于近日收到深圳证券交易所出具的《关于新希望六和股份 有限公司申请向特定对象发行股票的审核中心意见告知函》,深交所发行上市审核机构对公司向特定对 象发行股票的申请文件进行了审核,认为公司符合发行条件、上市条件和信息披露要求,后续深交所将 按规定报中国证券监督管理委员会履行相关注册程序。 新希望表示,公司本次向特定对象发行股票事项尚需获得中国证监会同意注册后方可实施,最终能 否获得中国证监会作出同意注册的决定及其时间尚存在不确定性。公司将根据该事项的进展情况按照相 关规定及时履行信息披露义务。 新希望昨日披露2023年度向特定对象发行A股股票预案(第三次修订稿)显示,本次向特定对象发行 A股股票的发行对象为不超过35名符合中国证监会规定条件的特定投资者,包括证券投资基金管理公 司、证券公司、信托公司、财务公司、保险机构投资者、合格境外机构投资者及其他符合法律法规规定 的法人、自然人或其他合格机构投资者。证券投资基金管理公司、证券公司、合格境外机构投资者、人 民币合格境外机 ...
立新能源2025年业绩预增超89%,定增项目进展受关注
Jing Ji Guan Cha Wang· 2026-02-13 07:10
经济观察网立新能源(001258)发布2025年业绩预告,预计净利润同比增长89.31%至119.20%,主要得 益于新增风电及储能项目投产,以及联营企业项目贡献投资收益。公司向特定对象发行股票(定增)事项 目前处于已问询阶段,募资额及部分项目投资额有所调减。 公司项目推进 新增风电及储能项目已于2025年投产,联营企业项目持续贡献收益。这些项目的后续运营情况可能影响 公司业绩。 业绩经营情况 以上内容基于公开资料整理,不构成投资建议。 公司于2026年1月29日发布2025年度业绩预告,预计归属于上市公司股东的净利润为9,500万元至11,000 万元,同比增长89.31%至119.20%。业绩增长主要因新增风电及独立储能项目投产带来上网电量增加, 以及联营企业"疆电外送"三通道发电项目投运贡献投资收益。2025年年度报告尚未正式披露。 定增股票 公司定增事项处于已问询阶段。2025年,公司调减了募资额,其中补充流动资金部分下调1.5亿元,并 调减了"三塘湖20万千瓦/80万千瓦时储能+80万千瓦风电项目"的投资额。定增最终结果有待监管审核。 ...
路维光电可转债不赎回,定增预案通过董事会审议
Jing Ji Guan Cha Wang· 2026-02-13 07:08
Core Viewpoint - Lu Wei Optoelectronics has decided not to exercise the early redemption rights of its convertible bonds and plans to issue A-shares to specific investors. The company is making progress in its semiconductor mask technology, and the Xiamen production base project is advancing as scheduled [1][2][3]. Group 1: Convertible Bonds - The company will not exercise the early redemption rights for the "Lu Wei Convertible Bonds" despite triggering conditional redemption terms between December 17, 2025, and January 8, 2026. The board has confirmed that it will not redeem even if conditions are triggered again within the next three months, until April 8, 2026, when the triggering cycle will be recalculated [2]. Group 2: A-Share Issuance - On January 21, 2026, the company’s board approved a plan to issue A-shares to specific investors for the year 2026. This plan is subject to shareholder approval and regulatory agency approval, and further developments will be announced [3]. Group 3: Project Progress - The Xiamen high-generation high-precision photomask production base project is progressing, with the first phase of equipment procurement already started. Revenue is expected to be realized in the second half of 2026, aimed at enhancing high-precision mask production capacity to meet downstream demand [4]. Group 4: Product Development - The company has achieved mass production at the 180nm process node in the semiconductor mask field, with 130nm process products validated and in small-batch production. Additionally, research and validation for more advanced nodes, such as 28nm, are ongoing, indicating future technological iterations worth monitoring [5].
翔楼新材股价异动与定增无关,主力资金流入及业绩稳健是主因
Jing Ji Guan Cha Wang· 2026-02-13 05:55
股票近期走势 经济观察网翔楼新材(301160)近期股价异动与定增事项无直接关联,主要受市场资金流向、公司基本 面及行业环境影响。 近期公司完成2023年限制性股票激励计划第二个归属期股份上市,39名激励对象获授143.55万股,于 2026年2月10日流通。此外,公司向特定对象发行股票申请已于2025年12月获深交所受理,目前处于审 核阶段。 行业政策与环境 特殊钢材料行业受益于制造业复苏及高端材料需求增长。近期市场关注点包括部分上市公司询价转让活 跃,但翔楼新材未涉及相关事项。外部环境方面,有报道称美国可能调整钢铝关税政策,但对公司直接 影响有限。 以上内容基于公开资料整理,不构成投资建议。 2026年2月10日至13日,翔楼新材股价连续上涨,2月13日收盘价为68.40元,单日涨幅4.08%,成交额 2.27亿元。资金流向显示,2月10日、12日主力资金分别净流入1957.37万元和1775.31万元,散户资金则 净流出。同期融资余额上升,2月10日融资净买入1308.42万元。 业绩经营情况 公司2025年第三季度报告显示,前三季度营业收入11.05亿元,同比增长2.82%;归母净利润1.51亿元, ...
壶化股份定增进展及股价表现引关注
Jing Ji Guan Cha Wang· 2026-02-13 01:20
经济观察网壶化股份(003002)近7天(2026年2月6日至13日)热点事件主要集中在定增进展和股价表 现。以下按事件重要性分类输出,重要模块前置。 近期事件 壶化股份于2026年2月11日公告回复深圳证券交易所关于向特定对象发行股票的审核问询函,详细说明 了报告期内业绩波动原因及募投项目可行性。公司已完成问询函回复和申请文件更新,但定增事宜仍需 深交所审核及证监会注册,最终结果存在不确定性。此外,截至2026年2月10日,公司股东总户数为 12,454户。 股票近期走势 近7个交易日(2月9日至12日),壶化股份股价区间跌幅2.67%,振幅4.54%,最高价28.11元(2月9日),最 低价26.85元(2月12日)。2月12日收盘价26.99元,单日下跌1.39%,表现弱于大盘(上证指数涨0.05%)。技 术面显示短期处于空头行情,20日压力位34.01元,支撑位25.35元。 机构观点 机构预测显示,壶化股份2025年归母净利润预计同比增长89.26%至2.65亿元,2026年预计增长30.94%至 3.47亿元。当前市盈率(TTM)为29.66倍,市场舆情偏中性,机构评级以中性为主。 以上内容基于公 ...
震安科技定增局:新掌门左手满仓质押右手包圆认购7.4亿元新股 可转债项目因产能利用率畸低蚕食利润
Xin Lang Zheng Quan· 2026-02-12 12:39
Core Viewpoint - Zhenan Technology plans to raise up to RMB 740 million through a private placement, primarily for working capital and repaying bank loans, raising questions about the necessity and source of funds given the company's financial situation and past performance [1][2][5]. Group 1: Fundraising and Financial Situation - Zhenan Technology intends to issue up to 46,416,652 shares at a price of RMB 15.96 per share, aiming to raise no more than RMB 740.81 million [2]. - The company has raised a total of RMB 918 million through various means since its IPO, yet has only distributed RMB 89 million in dividends, indicating a significant disparity between fundraising and shareholder returns [12]. - As of the end of Q3 2025, Zhenan Technology reported RMB 596 million in cash, with total interest-bearing liabilities of approximately RMB 190 million, suggesting sufficient liquidity to cover short-term debts [7][8]. Group 2: Control and Governance Issues - The controlling shareholders, Ning Huaxiang and Zhou Jianqi, have pledged 100% of their shares in Zhenan Technology as collateral for loans, raising concerns about the stability of control and potential risks associated with high leverage [3][5]. - The recent acquisition of the controlling stake in Huachuang Sanxin by the same shareholders has led to increased control over Zhenan Technology, but the simultaneous pledge of shares for loans creates a paradox regarding the source of funds for the new share subscription [2][5]. Group 3: Past Investment Performance - Previous fundraising efforts have been marred by controversies, with projects failing to meet expected returns; for instance, the utilization rate of the intelligent damping equipment manufacturing base was only 13.3%, leading to significant asset impairment losses [9][10]. - The company has faced regulatory scrutiny due to issues related to accounting practices and internal controls, which have contributed to its ongoing financial losses [12][13]. Group 4: Future Performance and Incentives - Zhenan Technology has set ambitious performance targets for its new stock incentive plan, requiring significant revenue and profit growth over the next few years, which may be challenging given its recent financial history [14][15]. - The stock incentive plan includes granting 276,290 restricted shares to the new financial director at a price significantly below market value, raising questions about the rationale behind such incentives for a recently appointed executive [15].
长江产业集团全额认购广济药业定增股份,巩固控制权
Jing Ji Guan Cha Wang· 2026-02-12 12:38
Group 1 - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Yangtze Industry Investment Group, raising a total of no more than 600 million RMB [1] - The purpose of the private placement is to repay company loans and supplement working capital, aiming to optimize capital structure and enhance financial stability [1] - As of September 2025, Guangji Pharmaceutical's debt-to-asset ratio is 62.67%, and the company has experienced continuous losses since 2023, with a projected net loss of between 399 million RMB and 518 million RMB for 2025 [1] Group 2 - The main reasons for the losses include long-term low prices in the vitamin B2 market and intense market competition, which have prevented sales prices from recovering [1] - The company believes that the private placement will enhance its risk resistance and reflects the controlling shareholder's confidence in the company's future development, which is beneficial for consolidating control [1] - The vitamin B2 market is expected to enter a phase of moderate growth starting in 2026 due to adjustments in market demand and opportunities for cost reduction from technological upgrades [1]